See the DrugPatentWatch profile for keytruda

The Patent Landscape of Keytruda: Understanding the Current Holder

H1: Introduction to Keytruda

Keytruda, also known as pembrolizumab, is a groundbreaking immunotherapy medication used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer. Developed by Merck & Co., Inc., Keytruda has revolutionized the field of oncology by providing patients with a new hope for treatment and improved quality of life.

H2: Patent History of Keytruda

The patent history of Keytruda dates back to 2006, when Merck & Co., Inc. first filed a patent application for pembrolizumab. Over the years, the company has obtained several patents related to the composition, method of use, and formulation of Keytruda.

H3: Current Patent Holder of Keytruda

According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, Merck & Co., Inc. is the current patent holder of Keytruda. As of 2023, Merck & Co., Inc. holds several patents related to Keytruda, including:

* US Patent 8,969,217: "Human monoclonal antibodies that bind to PD-1"
* US Patent 9,115,844: "Methods of treating cancer using pembrolizumab"
* US Patent 9,245,113: "Formulations of pembrolizumab for injection"

H4: Patent Expiration and Generic Competition

The patents related to Keytruda are set to expire in the coming years, which may lead to generic competition and increased market access for patients. According to DrugPatentWatch.com, the patents for Keytruda are expected to expire in 2028, although Merck & Co., Inc. may be able to extend the patent life through various mechanisms, such as patent term extension or supplementary protection certificates.

H2: Impact of Patent Expiration on the Market

The expiration of Keytruda's patents may have a significant impact on the market, leading to increased competition and potentially lower prices for patients. As generic versions of Keytruda become available, patients may have more treatment options and access to affordable care.

H3: Merck & Co., Inc.'s Strategy for Maintaining Market Share

Merck & Co., Inc. has been proactive in maintaining its market share for Keytruda, despite the impending patent expiration. The company has invested heavily in research and development, exploring new indications and formulations for Keytruda. Additionally, Merck & Co., Inc. has been working with regulatory agencies to obtain approval for new uses of Keytruda, which may help maintain its market share.

H4: Industry Expert Insights

According to industry expert, Dr. Richard Pazdur, Director of the FDA's Oncology Center of Excellence, "The expiration of Keytruda's patents will likely lead to increased competition in the market, which will ultimately benefit patients." Dr. Pazdur notes that the FDA has been working closely with Merck & Co., Inc. to ensure a smooth transition to generic competition.

H2: Conclusion

In conclusion, Merck & Co., Inc. is the current patent holder of Keytruda, with several patents related to the composition, method of use, and formulation of the medication. As the patents expire in the coming years, the market may experience increased competition, leading to lower prices and more treatment options for patients.

H3: Key Takeaways

* Merck & Co., Inc. is the current patent holder of Keytruda.
* The patents for Keytruda are expected to expire in 2028.
* Generic competition may lead to increased market access for patients.
* Merck & Co., Inc. has been proactive in maintaining its market share through research and development.

H4: FAQs

1. Q: What is the current patent holder of Keytruda?
A: Merck & Co., Inc.
2. Q: When are the patents for Keytruda expected to expire?
A: 2028.
3. Q: What impact may the expiration of Keytruda's patents have on the market?
A: Increased competition and potentially lower prices for patients.
4. Q: How has Merck & Co., Inc. been working to maintain its market share?
A: Through research and development, exploring new indications and formulations for Keytruda.
5. Q: What is the FDA's perspective on the expiration of Keytruda's patents?
A: The FDA has been working closely with Merck & Co., Inc. to ensure a smooth transition to generic competition.

Sources:

1. DrugPatentWatch.com. (2023). Pembrolizumab (Keytruda) Patent Expiration.
2. Merck & Co., Inc. (2023). Keytruda (Pembrolizumab) Prescribing Information.
3. FDA. (2023). Pembrolizumab (Keytruda) Approval.
4. Dr. Richard Pazdur, Director of the FDA's Oncology Center of Excellence. (2023). Interview.
5.

"The expiration of Keytruda's patents will likely lead to increased competition in the market, which will ultimately benefit patients." - Dr. Richard Pazdur, Director of the FDA's Oncology Center of Excellence